Prestige Consumer Healthcare, Inc. (PBH)
46.19
+0.87
(+1.92%)
USD |
NYSE |
Nov 13, 16:00
46.16
-0.04
(-0.08%)
After-Hours: 19:59
Prestige Consumer Healthcare Enterprise Value : 4.270B for Nov. 13, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2026 | 4.270B |
| November 12, 2026 | 4.229B |
| November 11, 2026 | 4.174B |
| November 10, 2026 | 4.212B |
| November 09, 2026 | 4.151B |
| November 06, 2026 | 4.118B |
| November 05, 2026 | 4.181B |
| November 04, 2026 | 4.606B |
| November 03, 2026 | 4.429B |
| November 02, 2026 | 4.438B |
| October 30, 2026 | 4.406B |
| October 29, 2026 | 4.391B |
| October 28, 2026 | 4.346B |
| October 27, 2026 | 4.327B |
| October 26, 2026 | 4.363B |
| October 23, 2026 | 4.346B |
| October 22, 2026 | 4.425B |
| October 21, 2026 | 4.352B |
| October 20, 2026 | 4.420B |
| October 19, 2026 | 4.437B |
| October 16, 2026 | 4.447B |
| October 15, 2026 | 4.413B |
| October 14, 2026 | 4.375B |
| October 13, 2026 | 4.379B |
| October 12, 2026 | 4.403B |
| Date | Value |
|---|---|
| October 09, 2026 | 4.367B |
| October 08, 2026 | 4.350B |
| October 07, 2026 | 4.335B |
| October 06, 2026 | 4.282B |
| October 05, 2026 | 4.242B |
| October 02, 2026 | 4.226B |
| October 01, 2026 | 4.203B |
| September 30, 2026 | 4.255B |
| September 29, 2026 | 4.192B |
| September 28, 2026 | 4.201B |
| September 25, 2026 | 4.186B |
| September 24, 2026 | 4.141B |
| September 23, 2026 | 4.154B |
| September 22, 2026 | 4.239B |
| September 21, 2026 | 4.195B |
| September 18, 2026 | 4.109B |
| September 17, 2026 | 4.180B |
| September 16, 2026 | 4.198B |
| September 15, 2026 | 4.190B |
| September 14, 2026 | 4.234B |
| September 11, 2026 | 4.202B |
| September 10, 2026 | 4.221B |
| September 09, 2026 | 4.285B |
| September 08, 2026 | 4.337B |
| September 04, 2026 | 4.454B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Supernus Pharmaceuticals, Inc. | 1.408B |
| Phibro Animal Health Corp. | 2.166B |
| Structure Therapeutics, Inc. | 194.14M |
| ANI Pharmaceuticals, Inc. | 1.807B |
| Corcept Therapeutics, Inc. | 7.615B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 25.30M |
| Revenue (Quarterly) | 336.31M |
| Total Expenses (Quarterly) | 311.01M |
| EPS Diluted (Quarterly) | 0.5315 |
| Gross Profit Margin (Quarterly) | 48.71% |
| Profit Margin (Quarterly) | 7.52% |
| Earnings Yield | 7.03% |
| Operating Earnings Yield | 13.21% |
| Normalized Earnings Yield | 7.072 |